z-logo
open-access-imgOpen Access
The Milky Way: paediatric milk‐based dispersible tablets prepared by direct compression – a proof‐of‐concept study
Author(s) -
Orubu Samuel E. F.,
Hobson Nicholas J.,
Basit Abdul W.,
Tuleu Catherine
Publication year - 2017
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1111/jphp.12570
Subject(s) - friability , compaction , compression (physics) , immediate release , ingredient , materials science , food science , mathematics , medicine , chromatography , composite material , chemistry , ethyl cellulose , polymer
Objectives Dispersible tablets are proposed by the World Health Organization as the preferred paediatric formulation. It was hypothesised that tablets made from a powdered milk‐base that disperse in water to form suspensions resembling milk might be a useful platform to improve acceptability in children. Methods Milk‐based dispersible tablets containing various types of powdered milk and infant formulae were formulated. The influence of milk type and content on placebo tablet properties was investigated using a design‐of‐experiments approach. Responses measured included friability, crushing strength and disintegration time. Additionally, the influence of compression force on the tablet properties of a model formulation was studied by compaction simulation. Key findings Disintegration times increased as milk content increased. Compaction simulation studies showed that compression force influenced disintegration time. These results suggest that the milk content, rather than type, and compression force were the most important determinants of disintegration. Conclusion Up to 30% milk could be incorporated to produce 200 mg 10‐mm flat‐faced placebo tablets by direct compression disintegrating within 3 min in 5–10 ml of water, which is a realistic administration volume in children. The platform could accommodate 30% of a model active pharmaceutical ingredient (caffeine citrate).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom